Insider Trading disclosures for Renovaro Biosciences Inc

The latest disclosure was made by Nathen Fuentes in Renovaro Biosciences Inc where a trade of 250,000 Option to purchase shares of common stock done was reported to US exchanges on Jan. 21, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Nathen Fuentes	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	21 Jan 2025	250,000	250,000	-		-	Option to purchase shares of common stock
Maurice van Tilburg	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	21 Jan 2025	250,000	250,000 (0%)	0%		0	Common Stock
Maurice van Tilburg	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	21 Jan 2025	1,000,000	1,000,000	-		-	Option to purchase shares of common stock
James A. Mcnulty	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	04 Nov 2024	120,968	120,968	-		-	Option to purchase shares of common stock
Simon Tarsh	Interim CFO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	04 Nov 2024	58,500	58,500	-		-	Option to purchase shares of common stock
Douglas W. Calder	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	04 Nov 2024	120,968	120,968	-		-	Option to purchase shares of common stock
Mark A. Collins	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	04 Nov 2024	120,968	120,968	-		-	Option to purchase shares of common stock
David Weinstein	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Oct 2024	1,600,000	1,600,000	-		-	Option to purchase shares of common stock
David Weinstein	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Oct 2024	250,000	250,000 (0%)	0%		0	Common Stock
Avram Miller	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	23 Aug 2024	978,261	978,261	-		-	Option to Purchase Shares of Common Stock
Avram Miller	Director	Sale or transfer of securities back to the company at price $ 0.00 per share.	23 Aug 2024	833,333	166,667 (0%)	1%		0	Common Stock
Karen Brink	Director, Ten Percent Owner	Other type of transaction at price $ 0.00 per share.	12 Aug 2024	2,000,000	23,372,969 (50%)	4%		-	Common Stock
Karen Brink	Director, Ten Percent Owner	Other type of transaction at price $ 0.00 per share.	12 Aug 2024	2,000,000	25,372,969 (54%)	4%		-	Common Stock
Gregg H. Alton	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	25 Jun 2024	48,137	48,137	-		-	Option to purchase shares of common stock
Ruud Hendriks	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	25 Jun 2024	18,634	18,634	-		-	Option to purchase shares of common stock
James Sapirstein	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	25 Jun 2024	48,137	48,137	-		-	Option to purchase shares of common stock
Carol L. Brosgart	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	25 Jun 2024	42,857	42,857	-		-	Option to purchase shares of common stock
Rene Sindlev	Director, Ten Percent Owner	Grant, award, or other acquisition of securities at price $ 0.00 per share.	25 Jun 2024	62,112	62	-		-	Option to purchase shares of common stock
Jayne McNicol	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	25 Jun 2024	46,584	46,584	-		-	Option to purchase shares of common stock
Avram Miller	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	25 Jun 2024	18,634	18,634	-		-	Option to purchase shares of common stock
Karen Brink	Director, Ten Percent Owner	Other type of transaction at price $ 0.00 per share.	06 Jun 2024	1,853,517	25,372,969 (54%)	4%		-	Common Stock
Jayne McNicol	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	26 May 2024	52,817	52,817	-		-	Option to Purchase Common Stock
Simon Tarsh	Interim CFO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	11 Mar 2024	10,000	10,000	-		-	Option to purchase shares of common stock
James Sapirstein	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Mar 2024	28,196	28,196	-		-	Option to Purchase Common Stock
Sindlev Rene	Director, Ten Percent Owner		20 Feb 2024	471,699	13,605,297 (29%)	1%	0.5	250,000	Common Stock
Rene Sindlev	Director, Ten Percent Owner		20 Feb 2024	471,699	471,698	-		-	Warrant (Right to Buy)
Mark Dybul R.	Director, Chief Executive Officer	Sale or transfer of securities back to the company at price $ 0.00 per share.	13 Feb 2024	5,226	0	-		-	Option to Purchase Common Stock
Francois Binette	COO and Executive VP for R&D	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Feb 2024	40,000	40,000	-		-	Option to Purchase Common Stock
Rene Sindlev	Director, Ten Percent Owner		13 Feb 2024	70,126	0	-		-	Series A Convertible Preferred Stock
Luisa Puche	Chief Financial Officer	Sale or transfer of securities back to the company at price $ 0.00 per share.	13 Feb 2024	75,000	0	-		-	Option to Purchase Common Stock
Luisa Puche	Chief Financial Officer	Sale or transfer of securities back to the company at price $ 0.00 per share.	13 Feb 2024	60,000	0	-		-	Option to Purchase Common Stock
Puche Luisa	Chief Financial Officer	Sale or transfer of securities back to the company at price $ 0.00 per share.	13 Feb 2024	80,000	0	-		-	Option to Purchase Common Stock
Mark Dybul R.	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Feb 2024	7,563	7,563	-		-	Option to Purchase Common Stock
Puche Luisa	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Feb 2024	60,000	60,000	-		-	Option to Purchase Common Stock
Dybul Mark R.	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Feb 2024	5,226	5,226	-		-	Option to Purchase Common Stock
Dybul R. Mark	Director, Chief Executive Officer	Sale or transfer of securities back to the company at price $ 0.00 per share.	13 Feb 2024	350,000	0	-		-	Option to Purchase Common Stock
Rene Sindlev	Director, Ten Percent Owner		13 Feb 2024	701,260	13,133,598 (28%)	1%		-	Common Stock
Francois Binette	COO and Executive VP for R&D	Sale or transfer of securities back to the company at price $ 0.00 per share.	13 Feb 2024	65,000	0	-		-	Option to Purchase Common Stock
Francois Binette	COO and Executive VP for R&D	Sale or transfer of securities back to the company at price $ 0.00 per share.	13 Feb 2024	40,000	0	-		-	Option to Purchase Common Stock
Binette Francois	COO and Executive VP for R&D	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Feb 2024	65,000	65,000	-		-	Option to Purchase Common Stock
Dybul R. Mark	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Feb 2024	2,000,000	2,000,000	-		-	Option to Purchase Common Stock
Francois Binette	COO and Executive VP for R&D	Sale or transfer of securities back to the company at price $ 0.00 per share.	13 Feb 2024	65,000	0	-		-	Option to Purchase Common Stock
Francois Binette	COO and Executive VP for R&D	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Feb 2024	65,000	65,000	-		-	Option to Purchase Common Stock
Mark Dybul R.	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Feb 2024	300,000	300,000	-		-	Option to Purchase Common Stock
Puche Luisa	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Feb 2024	60,000	60,000	-		-	Option to Purchase Common Stock
Luisa Puche	Chief Financial Officer	Sale or transfer of securities back to the company at price $ 0.00 per share.	13 Feb 2024	60,000	0	-		-	Option to Purchase Common Stock
Puche Luisa	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Feb 2024	75,000	75,000	-		-	Option to Purchase Common Stock
R. Mark Dybul	Director, Chief Executive Officer	Sale or transfer of securities back to the company at price $ 0.00 per share.	13 Feb 2024	300,000	0	-		-	Option to Purchase Common Stock
Mark R. Dybul	Director, Chief Executive Officer	Sale or transfer of securities back to the company at price $ 0.00 per share.	13 Feb 2024	7,563	0	-		-	Option to Purchase Common Stock
Mark R. Dybul	Director, Chief Executive Officer	Sale or transfer of securities back to the company at price $ 0.00 per share.	13 Feb 2024	450,000	0	-		-	Option to Purchase Common Stock

Showing 1 to 50 of 148 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

79.34% Fall from 52W High

Insider Trading disclosures for Renovaro Biosciences Inc

The latest disclosure was made by Nathen Fuentes in Renovaro Biosciences Inc where a trade of 250,000 Option to purchase shares of common stock done was reported to US exchanges on Jan. 21, 2025.

Screeners based on Insider Trading and SAST parameters